Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Cholangiocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Oncogenic osteomalacia 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Hypophosphatemia 1Hematologic Neoplasms 1Glioblastoma 1Acrocephalosyndactylia 1

Interventions

infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypophosphatemia × infigratinib × Clear all
NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡